Advertisement for orthosearch.org.uk
You currently have no access to view or download this content. Please log in with your institutional or personal account if you should have access to through either of these
The Bone & Joint Journal Logo

Receive monthly Table of Contents alerts from The Bone & Joint Journal

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Oncology

Travel distance to tertiary sarcoma centres does not influence oncological presentation or outcomes



Download PDF

Abstract

Aims

Soft-tissue sarcomas (STSs) are rare cancers with centralized care advocated to consolidate resources and expertise. However, geographical challenges, particularly in countries like Canada, can increase travel distances for patients. The impact of travel distance on sarcoma presentation and outcomes remains unclear, particularly in single-payer healthcare systems with centralized care.

Methods

A retrospective cohort analysis was conducted on 1,570 patients with STS who underwent surgical resection at a Canadian tertiary referral centre between January 2010 and January 2021. Patients were divided into those living ≤ 50 km and > 50 km from the centre. Demographics, tumour characteristics, treatment methods, and survival outcomes were analyzed. A Cox regression model was constructed to evaluate predictors of overall survival.

Results

Patients living > 50 km from the centre (n = 700) travelled a mean of 176 km (SD 250), while those ≤ 50 km (n = 870) travelled a mean of 24.8 km (SD 13.8). There were no significant differences in disease presentation, time to definitive treatment, use of systemic therapies, or functional outcomes between the two groups. The two-year and five-year overall survival rates were similar between the groups (83.1% (95% CI 80.1% to 86.1%) vs 83.8% (95% CI 81.8% to 85.8%) and 72.1% (95% CI 69.1% to 75.1%) vs 72.5% (95% CI 69.5% to 75.5%), respectively). The regression model demonstrated that age, higher tumour grade, depth, and lower income were predictive of worse overall survival, while distance travelled was not an independent predictor of survival.

Conclusion

Contrary to previous studies, our findings suggest that travel distance did not influence disease presentation or survival outcomes in STS patients treated at a centralized sarcoma centre. This challenges previous notions regarding the impact of travel distance on cancer outcomes, and supports the effectiveness of centralized care models, even in geographically vast regions.

Cite this article: Bone Joint J 2025;107-B(3):368–372.


Correspondence should be sent to Aaron Gazendam. E-mail:

For access options please click here